AHNS 2013 Annual Meeting - American Head and Neck Society
AHNS 2013 Annual Meeting - American Head and Neck Society
AHNS 2013 Annual Meeting - American Head and Neck Society
- No tags were found...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Scientific Session Thursday, April 11, <strong>2013</strong>2:15 - 3:15 PM Panel: Evidence Based Mediterranean 5Management of Oral Cavity CancerPanel Moderators: Brian Nussenbaum, MD <strong>and</strong>Hadi Seikaly, MD, FRCSCThis panel will review <strong>and</strong> discuss current practices in themanagement of oral cavity carcinoma. Using evidencebased medicine <strong>and</strong> data to support the expert opinions,the current role surgery (including considerationsof biomarkers), role of chemoradiation as definitiveor adjuvant therapy, <strong>and</strong> the role of reconstruction(particularly focusing on glossectomy <strong>and</strong> lateralm<strong>and</strong>ibulectomy defects) in the treatment of oral cavitycarcinoma will be highlighted.2:15 PM Evidence for Surgery: Will Management Eduardo Mendez, MDDecisions Change with the Use of Biomarkers in <strong>2013</strong>2:30 PM Evidence for Definitive or Adjunctive Kerstin M. Stenson, MDUse of Chemoradiation: St<strong>and</strong>ard Therapy in <strong>2013</strong>2:45 PM Evidence for Reconstruction: Eric Genden, MDReporting Functional Outcomes in <strong>2013</strong>3:00 PM Panel Discussion All PanelistsAt the conclusion of this session, participants will be able to:• Describe NCCN guidelines for management of oral cavitycancer• Discuss evidence based principles for the appropriate use ofsurgery, radiation, <strong>and</strong> chemoradiation in the managementof oral cavity patients, <strong>and</strong> how to incorporate thesetherapies in the most effective manner• Underst<strong>and</strong> how to make treatment decisions regardingreconstruction of oral cavity defects, with the abundance ofexpert opinion <strong>and</strong> lack of comparative effectiveness studies• Recognize the emerging role of using biomarkers in thispatient population <strong>and</strong> how these biomarkers may beincorporated into future evidence based medicine treatmentguidelinesThe <strong>AHNS</strong> acknowledges a generous educational grantin support of this panel from CelSci Corporation.Wednesday, April 10, <strong>2013</strong> Thursday, April 11, <strong>2013</strong>3:15 - 3:45 PM Afternoon Break Coquina Ballroom3:45 - 4:45 PM Scientific Session #6: Mediterranean 5Basic ScienceModerators: Eduardo Mendez, MD <strong>and</strong>Wendell G. Yarbrough, MD3:45 PM S028: FOLATE RECEPTOR BETA TARGETING FOR INVIVO OPTICALIMAGING OF HEAD AND NECK SQAMOUIS CELL CARCINOMA. JoelY Sun, Joel Thibodeaux, Gang Huang, Yiguang Wang, Jingming Gao,Philip S Low, Baran D Sumer; University of Texas SouthwesternMedical Center; Purdue University.3:53 PM S029: DECITABINE AND CISPLATIN COMBINATION THERAPY FORHEAD AND NECK SQUAMOUS CELL CARCINOMA. Chi T Viet, DDS,PhD, Dongmin Dang, MD, Yi Ye, PhD, Brian L Schmidt, DDS, MD, PhD;New York University, Bluestone Center for Clinical Research.*Best Resident Basic Science Paper Award Winner4:01 PM S030: USE OF RETINOBLASTOMA PROTEIN (PRB)IMMUNOHISTOCHEMICAL STAINING AS A PROGNOSTIC INDICATORIN OROPHARYNGEAL SQUAMOOUS CELL CARCINOMA. Adam LBaker, MD, Joseph Curry, MD, Gao W, BS, Cognetti D, MD, T Zhan,PhD, V Bar-Ad, MD, M Tuluc, MD; Thomas Jefferson University,Departments of Otolaryngology, Radiation Oncology, <strong>and</strong>Pathology.April 10 - 11, <strong>2013</strong> · www.ahns.info 45
Change language